Efficacy and safety of human menopausal gonadotrophins versus recombinant FSH: a meta-analysis (Q46593837)

23 December 2017

meta-analysis

0 references

title

Efficacy and safety of human menopausal gonadotrophins versus recombinant FSH: a meta-analysis (English)

1 reference

23 December 2017

0 references

Hesham G Al-Inany

1

1 reference

23 December 2017

Ahmed M Abou-Setta

2

1 reference

23 December 2017

Mohamed A Aboulghar

3

1 reference

23 December 2017

Ragaa T Mansour

4

1 reference

23 December 2017

Gamal I Serour

5

1 reference

23 December 2017

publication date

1 January 2008

1 reference

23 December 2017

Reproductive BioMedicine Online

published in

1 reference

23 December 2017

volume

16

1 reference

23 December 2017

issue

1

1 reference

23 December 2017

page(s)

81-88

1 reference

23 December 2017

Ovulation induction in the new millennium: recombinant follicle-stimulating hormone versus human menopausal gonadotropin

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960559-7

7 January 2021

Meta-analysis of recombinant versus urinary-derived FSH: an update

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960559-7

7 January 2021

Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960559-7

7 January 2021

Ovarian responses to recombinant FSH or HMG in normogonadotrophic women following pituitary desensitization by a depot GnRH agonist for assisted reproduction

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960559-7

7 January 2021

Pure and highly purified follicle-stimulating hormone alone or in combination with human menopausal gonadotrophin for ovarian stimulation after pituitary suppression in in-vitro fertilization.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960559-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960559-7

1 reference

7 January 2021

Recombinant follicle-stimulating hormone versus human menopausal gonadotropin in the late follicular phase during ovarian hyperstimulation for in vitro fertilization.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960559-7

7 January 2021

The number needed to treat: a clinically useful measure of treatment effect

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960559-7

7 January 2021

Efficacy and safety of highly purified menotropin versus recombinant follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection cycles: a randomized, comparative trial

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960559-7

7 January 2021

A randomized prospective assessor-blind evaluation of luteinizing hormone dosage and in vitro fertilization outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960559-7

7 January 2021

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960559-7

7 January 2021

A prospective randomized clinical trial comparing recombinant follicle stimulating hormone (Puregon) and human menopausal gonadotrophins (Humegon) in non-down-regulated in-vitro fertilization patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960559-7

7 January 2021

A prospective, randomized, controlled trial comparing highly purified hMG with recombinant FSH in women undergoing ICSI: ovarian response and clinical outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960559-7

7 January 2021

Ovarian response and in vitro fertilization outcome in patients with reduced ovarian reserve who were stimulated with recombinant follicle-stimulating hormone or human menopausal gonadotropin

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960559-7

7 January 2021

HMG is as good as recombinant human FSH in terms of oocyte and embryo quality: a prospective randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960559-7

7 January 2021

Recombinant follicle stimulating hormone (rFSH; Puregon) in assisted reproduction: more oocytes, more pregnancies. Results from five comparative studies

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960559-7

7 January 2021

The effect of HMG and recombinant human FSH on oocyte quality: a randomized single-blind clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960559-7

7 January 2021

Endocrine profile in serum and follicular fluid differs after ovarian stimulation with HP-hMG or recombinant FSH in IVF patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960559-7

7 January 2021

Human chorionic gonadotropin in commercial human menopausal gonadotropin preparations

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960559-7

7 January 2021

Impact of recombinant follicle-stimulating hormone and human menopausal gonadotropins on in vitro fertilization outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960559-7

7 January 2021

The cost-effectiveness of IVF in the UK: a comparison of three gonadotrophin treatments.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960559-7

7 January 2021

Compositional analyses of a human menopausal gonadotrophin preparation extracted from urine (menotropin). Identification of some of its major impurities

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960559-7

7 January 2021

Human menopausal gonadotropin versus recombinant follicle-stimulating hormone in normogonadotropic women down-regulated with a gonadotropin-releasing hormone agonist who were undergoing in vitro fertilization and intracytoplasmic sperm injection: a

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960559-7

7 January 2021

Beta blockade during and after myocardial infarction: an overview of the randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960559-7

7 January 2021

Influence of ovarian stimulation with HP-hMG or recombinant FSH on embryo quality parameters in patients undergoing IVF.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960559-7

7 January 2021

Characterization of human chorionic gonadotropin as a novel angiogenic factor

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960559-7

7 January 2021

Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD003973

Identifiers

DOI

10.1016/S1472-6483(10)60559-7

1 reference

23 December 2017

PubMed ID

18252052

1 reference

23 December 2017